Evolent Health (EVH) Scheduled to Post Earnings on Thursday

Evolent Health (NYSE:EVH) will be posting its quarterly earnings results after the market closes on Thursday, August 8th. Analysts expect Evolent Health to post earnings of $0.21 per share for the quarter. Evolent Health has set its FY 2024 guidance at EPS and its Q2 2024 guidance at EPS.Individual interested in registering for the company’s earnings conference call can do so using this link.

Evolent Health (NYSE:EVH) last posted its earnings results on Thursday, May 9th. The technology company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.04. Evolent Health had a negative net margin of 5.07% and a positive return on equity of 6.90%. The firm had revenue of $639.65 million during the quarter, compared to the consensus estimate of $601.60 million. On average, analysts expect Evolent Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Evolent Health Stock Up 3.6 %

Evolent Health stock opened at $21.78 on Wednesday. Evolent Health has a fifty-two week low of $17.98 and a fifty-two week high of $35.00. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.02 and a current ratio of 1.02. The firm has a 50 day moving average price of $21.32 and a 200 day moving average price of $26.85. The company has a market capitalization of $2.53 billion, a PE ratio of -17.42 and a beta of 1.54.

Analyst Ratings Changes

EVH has been the subject of several research reports. Citigroup initiated coverage on shares of Evolent Health in a report on Monday, April 22nd. They issued a “buy” rating and a $40.00 target price for the company. JMP Securities dropped their target price on shares of Evolent Health from $38.00 to $34.00 and set a “market outperform” rating for the company in a report on Friday, May 10th. Stephens reiterated an “overweight” rating and issued a $42.00 target price on shares of Evolent Health in a report on Tuesday, July 30th. Finally, Canaccord Genuity Group dropped their price target on shares of Evolent Health from $44.00 to $41.00 and set a “buy” rating for the company in a research note on Friday, May 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.